Daptomycin API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510244774

Publication Date:

October 25, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Daptomycin API in this report.
The global market for Daptomycin API was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Daptomycin API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Daptomycin API by region & country, by Type, and by Application.
The Daptomycin API market size, estimations, and forecasts are provided in terms of sales volume (MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Daptomycin API.
Market Segmentation
By Company
Xellia Pharmaceuticals
Rochem International Inc
Tecoland Corporation
Livzon Group Fuzhou Fuxing Pharmaceutical Co
Chongqing DaXin Pharmaceutical Co
Suzhou Pharmaceutical Technology Co
Huazhong Pharmaceutical Co
Athos
Segment by Type:
99%
98%
Others
Segment by Application
350mg/vial
500mg/vial
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Daptomycin API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Daptomycin API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Daptomycin API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Daptomycin API Product Introduction
1.2 Global Daptomycin API Market Size Forecast
1.2.1 Global Daptomycin API Sales Value (2019-2030)
1.2.2 Global Daptomycin API Sales Volume (2019-2030)
1.2.3 Global Daptomycin API Sales Price (2019-2030)
1.3 Daptomycin API Market Trends & Drivers
1.3.1 Daptomycin API Industry Trends
1.3.2 Daptomycin API Market Drivers & Opportunity
1.3.3 Daptomycin API Market Challenges
1.3.4 Daptomycin API Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Daptomycin API Players Revenue Ranking (2023)
2.2 Global Daptomycin API Revenue by Company (2019-2024)
2.3 Global Daptomycin API Players Sales Volume Ranking (2023)
2.4 Global Daptomycin API Sales Volume by Company Players (2019-2024)
2.5 Global Daptomycin API Average Price by Company (2019-2024)
2.6 Key Manufacturers Daptomycin API Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Daptomycin API Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Daptomycin API
2.9 Daptomycin API Market Competitive Analysis
2.9.1 Daptomycin API Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Daptomycin API Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Daptomycin API as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 99%
3.1.2 98%
3.1.3 Others
3.2 Global Daptomycin API Sales Value by Type
3.2.1 Global Daptomycin API Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Daptomycin API Sales Value, by Type (2019-2030)
3.2.3 Global Daptomycin API Sales Value, by Type (%) (2019-2030)
3.3 Global Daptomycin API Sales Volume by Type
3.3.1 Global Daptomycin API Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Daptomycin API Sales Volume, by Type (2019-2030)
3.3.3 Global Daptomycin API Sales Volume, by Type (%) (2019-2030)
3.4 Global Daptomycin API Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 350mg/vial
4.1.2 500mg/vial
4.1.3 Others
4.2 Global Daptomycin API Sales Value by Application
4.2.1 Global Daptomycin API Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Daptomycin API Sales Value, by Application (2019-2030)
4.2.3 Global Daptomycin API Sales Value, by Application (%) (2019-2030)
4.3 Global Daptomycin API Sales Volume by Application
4.3.1 Global Daptomycin API Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Daptomycin API Sales Volume, by Application (2019-2030)
4.3.3 Global Daptomycin API Sales Volume, by Application (%) (2019-2030)
4.4 Global Daptomycin API Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Daptomycin API Sales Value by Region
5.1.1 Global Daptomycin API Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Daptomycin API Sales Value by Region (2019-2024)
5.1.3 Global Daptomycin API Sales Value by Region (2025-2030)
5.1.4 Global Daptomycin API Sales Value by Region (%), (2019-2030)
5.2 Global Daptomycin API Sales Volume by Region
5.2.1 Global Daptomycin API Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Daptomycin API Sales Volume by Region (2019-2024)
5.2.3 Global Daptomycin API Sales Volume by Region (2025-2030)
5.2.4 Global Daptomycin API Sales Volume by Region (%), (2019-2030)
5.3 Global Daptomycin API Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Daptomycin API Sales Value, 2019-2030
5.4.2 North America Daptomycin API Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Daptomycin API Sales Value, 2019-2030
5.5.2 Europe Daptomycin API Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Daptomycin API Sales Value, 2019-2030
5.6.2 Asia Pacific Daptomycin API Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Daptomycin API Sales Value, 2019-2030
5.7.2 South America Daptomycin API Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Daptomycin API Sales Value, 2019-2030
5.8.2 Middle East & Africa Daptomycin API Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Daptomycin API Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Daptomycin API Sales Value
6.2.1 Key Countries/Regions Daptomycin API Sales Value, 2019-2030
6.2.2 Key Countries/Regions Daptomycin API Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Daptomycin API Sales Value, 2019-2030
6.3.2 United States Daptomycin API Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Daptomycin API Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Daptomycin API Sales Value, 2019-2030
6.4.2 Europe Daptomycin API Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Daptomycin API Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Daptomycin API Sales Value, 2019-2030
6.5.2 China Daptomycin API Sales Value by Type (%), 2023 VS 2030
6.5.3 China Daptomycin API Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Daptomycin API Sales Value, 2019-2030
6.6.2 Japan Daptomycin API Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Daptomycin API Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Daptomycin API Sales Value, 2019-2030
6.7.2 South Korea Daptomycin API Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Daptomycin API Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Daptomycin API Sales Value, 2019-2030
6.8.2 Southeast Asia Daptomycin API Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Daptomycin API Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Daptomycin API Sales Value, 2019-2030
6.9.2 India Daptomycin API Sales Value by Type (%), 2023 VS 2030
6.9.3 India Daptomycin API Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Xellia Pharmaceuticals
7.1.1 Xellia Pharmaceuticals Company Information
7.1.2 Xellia Pharmaceuticals Introduction and Business Overview
7.1.3 Xellia Pharmaceuticals Daptomycin API Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Xellia Pharmaceuticals Daptomycin API Product Offerings
7.1.5 Xellia Pharmaceuticals Recent Development
7.2 Rochem International Inc
7.2.1 Rochem International Inc Company Information
7.2.2 Rochem International Inc Introduction and Business Overview
7.2.3 Rochem International Inc Daptomycin API Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Rochem International Inc Daptomycin API Product Offerings
7.2.5 Rochem International Inc Recent Development
7.3 Tecoland Corporation
7.3.1 Tecoland Corporation Company Information
7.3.2 Tecoland Corporation Introduction and Business Overview
7.3.3 Tecoland Corporation Daptomycin API Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Tecoland Corporation Daptomycin API Product Offerings
7.3.5 Tecoland Corporation Recent Development
7.4 Livzon Group Fuzhou Fuxing Pharmaceutical Co
7.4.1 Livzon Group Fuzhou Fuxing Pharmaceutical Co Company Information
7.4.2 Livzon Group Fuzhou Fuxing Pharmaceutical Co Introduction and Business Overview
7.4.3 Livzon Group Fuzhou Fuxing Pharmaceutical Co Daptomycin API Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Livzon Group Fuzhou Fuxing Pharmaceutical Co Daptomycin API Product Offerings
7.4.5 Livzon Group Fuzhou Fuxing Pharmaceutical Co Recent Development
7.5 Chongqing DaXin Pharmaceutical Co
7.5.1 Chongqing DaXin Pharmaceutical Co Company Information
7.5.2 Chongqing DaXin Pharmaceutical Co Introduction and Business Overview
7.5.3 Chongqing DaXin Pharmaceutical Co Daptomycin API Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Chongqing DaXin Pharmaceutical Co Daptomycin API Product Offerings
7.5.5 Chongqing DaXin Pharmaceutical Co Recent Development
7.6 Suzhou Pharmaceutical Technology Co
7.6.1 Suzhou Pharmaceutical Technology Co Company Information
7.6.2 Suzhou Pharmaceutical Technology Co Introduction and Business Overview
7.6.3 Suzhou Pharmaceutical Technology Co Daptomycin API Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Suzhou Pharmaceutical Technology Co Daptomycin API Product Offerings
7.6.5 Suzhou Pharmaceutical Technology Co Recent Development
7.7 Huazhong Pharmaceutical Co
7.7.1 Huazhong Pharmaceutical Co Company Information
7.7.2 Huazhong Pharmaceutical Co Introduction and Business Overview
7.7.3 Huazhong Pharmaceutical Co Daptomycin API Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Huazhong Pharmaceutical Co Daptomycin API Product Offerings
7.7.5 Huazhong Pharmaceutical Co Recent Development
7.8 Athos
7.8.1 Athos Company Information
7.8.2 Athos Introduction and Business Overview
7.8.3 Athos Daptomycin API Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Athos Daptomycin API Product Offerings
7.8.5 Athos Recent Development
8 Industry Chain Analysis
8.1 Daptomycin API Industrial Chain
8.2 Daptomycin API Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Daptomycin API Sales Model
8.5.2 Sales Channel
8.5.3 Daptomycin API Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Xellia Pharmaceuticals
Rochem International Inc
Tecoland Corporation
Livzon Group Fuzhou Fuxing Pharmaceutical Co
Chongqing DaXin Pharmaceutical Co
Suzhou Pharmaceutical Technology Co
Huazhong Pharmaceutical Co
Athos

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂